Cole Pharmaceuticals 1A

Improving peoples' lives by redefining Vitamin D treatments
total amount raised in round
  • Backed by over 140 investors
  • Eligible for a tax reduction
This campaign has been closed

Claude Lubicki


Claude Lubicki (French), the CEO, over 30 years of pharmaceutical and biotech industry experience and consulting. Prior to co-founding Cole Pharmaceuticals, Claude Lubicki was most recently, the business development representative in Europe of Endoceutics, a Canadian bio-pharmaceutical company. In this role, he successfully closed seven out-licensing deals. In his wealth of international experience, Claude Lubicki has held senior positions in pharmaceutical companies such as GSK, Orion Pharma, Menarini, Grünenthal spanning General Management, Business Development, Global Marketing. His experience covers a wide array of therapeutic areas.

Jean-Marie Vandeplas


Jean-Marie Vandeplas (Belgian), the Chief Commercial Officer, has over 30 years of experience in pharmaceutical companies in various sales and marketing positions. He has an extensive experience in Women’s Health Care including osteoporosis and vitamin D. Jean-Marie Vandeplas began his career at Organon. Today, Jean-Marie Vandeplas works as a consultant in the pharmaceutical industry. He has completed several missions in Marketing Strategy and Business Development for companies such as Wyeth, Merck KGAA, Johnson & Johnson, Will-Pharma, Mithra Pharmaceuticals, Besins HealthCare, Novadip.

Christian Huyghe


Christian Huyghe (Belgium), a doctor by training and is the acting Chief Scientific Officer. Christian has over 25 years of experience in the pharmaceutical industry and is also a recognized Market Access consultant. He has worked for companies such as Organon, Wyeth, Servier and Sanofi.